Find a Quick Antivirus Option

Find a Quick Antivirus Option

Blog Article

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

Research advances in the realm of antiviral therapies since the pandemic began have been considerable. At the same time, no medicine is perfect. The concern is that if not deployed properly, the effectiveness and longevity of antiviral treatments may be compromised.

So let’s take a look at what’s in the antivirals arms locker, and how we got to this point.

In 2020, the priority was drug repurposing (identifying medicines for keflex generic other conditions that might also benefit COVID patients). Success with drugs like dexamethasone followed. This is a steroid which counters the inflammation that occurs as a result of the body’s overactive immune response during severe COVID.

Things didn’t go as smoothly for direct-acting antivirals, a group of drugs that target the virus directly to suppress infection. So desperate was the situation early in the pandemic that agents like hydroxychloroquine and ivermectin were tested in clinical trials and, predictably, were found wanting.

One promising candidate, however, did emerge during 2020. Remdesivir is a ribonucleotide analogue (or “nuc”) that mimics the building blocks of the virus’ genetic material. It poisons the copying process by not allowing further links to be added to RNA chains. Remdesivir was first developed as a potential cure for hepatitis C.

Despite working well against SARS-CoV-2 (the virus that causes COVID) in pre-clinical settings, initial trials in patients with severe COVID were conflicted.

We now know that COVID can progress fairly quickly from a virus-driven disease to the severe sepsis-like consequences of a misfiring immune response. So direct-acting antivirals must be deployed early. A trial where remdesivir was given to high-risk patients soon after infection found an 87% reduced risk of hospitalisation or death compared with a placebo.

An illustration of SARS-CoV-2, the coronavirus that causes COVID-19.

Another nuc, molnupiravir, becomes incorporated within RNA chains, generating a drug-laden template that corrupts the next copy. Before the pandemic, molnupiravir had been explored for influenza and other viruses. Against effexor 37,5 mg no prescription COVID, it reduced the risk of hospitalisation and death, but only by roughly 30%, despite performing well in lab settings.

Paxlovid, produced by Pfizer, combines two different drugs. Nirmatrelvir, a modified version of an antiviral originally developed for SARS, prevents the virus from replicating.

Ritonavir is not an antiviral, but a potent inhibitor of the liver metabolism, allowing nirmatrelvir to persist for longer in the body and act more efficiently. In trials, Paxlovid saw a reduction in hospitalisations and deaths similar to remdesivir.

Paxlovid and molnupiravir are taken orally, whereas remdesivir is administered intravenously. The approval statuses of these direct-acting antivirals varies in different regions, though remdesivir and Paxlovid are available fairly widely. While all three drugs are conditionally approved and currently available in the UK, the availability of molnupiravir is more limited around the world.


Report this page